Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28327332 | 0.85 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HSD17B10MAPTKMT2A | |
| SCHEMBL22092310 | 0.81 | DRD2 (0.63) | ALDH1A1DRD2DRD3HTR1ADRD4 | |
| SCHEMBL6227687 | 0.81 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2HSD17B10MAPTKMT2A | |
| SCHEMBL1163277 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2HSD17B10MAPTKMT2A | |
| SCHEMBL13382891 | 0.78 | DRD2 (0.53) | ALDH1A1SMN1; SMN2DRD2DRD3HSD17B10 | |
| SCHEMBL6435087 | 0.77 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2DRD2DRD3HSD17B10 | |
| SCHEMBL735202 | 0.77 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2DRD2DRD3HSD17B10 | |
| SCHEMBL8550773 | 0.77 | DRD4 (0.55) | ALDH1A1DRD2DRD3DRD4MAPT | |
| SCHEMBL8253295 | 0.77 | TP53 (0.48) | ALDH1A1SMN1; SMN2HSD17B10MAPTKMT2A | |
| SCHEMBL28452031 | 0.76 | KMT2A (0.46) | ALDH1A1MAPTKMT2ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727794-B1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PROD INC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263484-A1 | SINGLE CHAIN FC TYPE III INTERFERONS AND METHODS OF USING SAME | ZYMOGENETICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7479559-B2 | 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation | PFIZER INC. (US) | 2009-01-20 | — | — | US | disclosed |
| CN-1934081-A | Novel benayl(idene)-lactam derivatives | PFIZER (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1727794-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | Pfizer Products Incorporated (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1697353-A2 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS WITH AFFINITY FOR 5-HT1 RECEPTORS | Pfizer Products Incorporated (US) | 2006-09-06 | — | — | EP | disclosed |
| CN-1239497-C | Intermediate product for preparing aralkyl and aryl alkylene heterocyclic lactam and imide | PFIZER (US) | 2006-02-01 | — | — | CN | disclosed |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | PFIZER INC. | 2005-11-03 | — | — | US | disclosed |
| US-20050227980-A1 | Aralkyl and aralkylidene heterocyclic lactam and imides | PFIZER INC. | 2005-10-13 | — | — | US | disclosed |
| US-20050227981-A1 | Aralkyl and aralkylidene heterocyclic lactam and imides | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002046167-A1 | BENZYL (IDENE)-LACTAMS AND THEIR USE AS 5HT1-RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | disclosed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| CN-1329002-A | Intermediate product for preparing aralkyl and aryl alkylene heterocyclic lactam and imide | PFIZER (US) | 2002-01-02 | — | — | CN | disclosed |
| CN-1231661-A | Lactams and imides of aralkyl and arylalkylene heterocycles | PFIZER (US) | 1999-10-13 | — | — | CN | disclosed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ALDH1A1 1434/4885SMN1; SMN2 2469/4885DRD2 84/4885 |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | HTR1E, HTR1D, HTR1A | ALDH1A1 411/4885SMN1; SMN2 2257/4885DRD2 69/4885 |
| US-20050227981-A1 | Aralkyl and aralkylidene heterocyclic lactam and imides | ARAF, MRPL21, ACSL3 | ALDH1A1 1132/4885SMN1; SMN2 2882/4885DRD2 166/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | ALDH1A1 1607/4885SMN1; SMN2 2396/4885DRD2 94/4885 |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | ALDH1A1 1607/4885SMN1; SMN2 2396/4885DRD2 94/4885 |
| US-20050227980-A1 | Aralkyl and aralkylidene heterocyclic lactam and imides | ARAF, MRPL21, ACSL3 | ALDH1A1 1132/4885SMN1; SMN2 2882/4885DRD2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.